Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526603 · ClinicalTrials.gov registry record · NA
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT01526603: Completed NA study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT01526603 is a NA study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01526603, a NA study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a standard of care document, outlining the therapy for children with high risk neuroblastoma who are not eligible for Children's Oncology Group (COG) studies.
Primary Outcome
The time to neutrophil engraftment will be assessed by standard statistical approaches.
Interventions
- DRUG Carboplatin
- RADIATION Radiation therapy
- BIOLOGICAL Autologous stem cell infusion
- BIOLOGICAL Granulocyte colony stimulating factor
- DRUG Isotretinoin (13-cis-retinoic acid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-03-28 |
| Est. Completion | 2023-05-30 |
| Phase | NA |
What the finished NCT01526603 record still lists
NCT01526603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01526603 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01526603 about?
NCT01526603 is a clinical study titled "High Dose Chemotherapy and Autologous Transplant for Neuroblastoma". This is a standard of care document, outlining the therapy for children with high risk neuroblastoma who are not eligible for Children's Oncology Group (COG) studies.
What is the current status of trial NCT01526603?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2012-03-28. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT01526603?
The interventions under investigation include: Carboplatin (DRUG), Radiation therapy (RADIATION), Autologous stem cell infusion (BIOLOGICAL), Granulocyte colony stimulating factor (BIOLOGICAL), Isotretinoin (13-cis-retinoic acid) (DRUG).
Who is sponsoring clinical trial NCT01526603?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01526603's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI